Werewolf Therapeutics, Inc.
HOWL
$0.71
$0.0568.56%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -100.00% | -- | -85.86% | -83.38% | -79.39% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -100.00% | -- | -85.86% | -83.38% | -79.39% |
| Cost of Revenue | 82.64% | 15.59% | 59.36% | 10.27% | -48.07% |
| Gross Profit | -134.58% | -153.55% | -840.61% | -67.99% | 8.54% |
| SG&A Expenses | 3.68% | 6.64% | 5.85% | 0.30% | 3.73% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 40.69% | 13.04% | 42.09% | 7.29% | -29.32% |
| Operating Income | -56.98% | -85.10% | -212.51% | -40.41% | 1.65% |
| Income Before Tax | -69.96% | -101.24% | -238.35% | -35.14% | -0.61% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -69.96% | -101.24% | -238.35% | -35.14% | -0.61% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -69.96% | -101.24% | -238.35% | -35.14% | -0.61% |
| EBIT | -56.98% | -85.10% | -212.51% | -40.41% | 1.65% |
| EBITDA | -59.22% | -89.30% | -228.53% | -41.53% | 2.04% |
| EPS Basic | -39.76% | -64.16% | -176.36% | -12.98% | 15.46% |
| Normalized Basic EPS | -39.79% | -64.19% | -167.63% | -12.96% | 15.46% |
| EPS Diluted | -39.76% | -64.16% | -196.65% | -12.98% | 15.46% |
| Normalized Diluted EPS | -39.79% | -64.19% | -164.40% | -12.96% | 15.46% |
| Average Basic Shares Outstanding | 21.62% | 22.58% | 22.40% | 19.61% | 18.99% |
| Average Diluted Shares Outstanding | 21.62% | 22.58% | 23.86% | 19.61% | 18.99% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
